Prevalence of Pathogenic Genetic Variants Across Heart Failure Etiologies in an Admixed Population
4 affiliations
- 1Laboratorio de Genetica e Cardiologia Molecular, Instituto do Coração (InCor), Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
- 2Institut de Biologia Evolutiva, Departament de Medicina i Ciències de la Vida, Universitat Pompeu Fabra, Barcelona, Spain
- 3Departamento de Genética e Biologia Evolutiva, Instituto de Biociências, Universidade de São Paulo, São Paulo, São Paulo, Brazil
- 4Aging Division, Brigham and Women’s Hospital, Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
Abstract
Background: Heart failure (HF) has multiple etiologies, but genetic testing remains mainly recommended for selected subgroups with suspected inherited cardiomyopathy.
Objectives: This study identified and classified genetic variants in patients within a HF cohort with reduced ejection fraction or mildly reduced ejection fraction from diverse etiologies in an admixed population.
Methods: The authors analyzed whole-genome sequencing data from 1,013 unrelated individuals in the GENIUS-HF (Genetic and ElectroNic medIcal records to predict oUtcomeS in Heart Failure patients) cohort. Rare variants in 123 ClinGen-curated cardiovascular genes were classified according to American College of Medical Genetics and Genomics (ACMG) criteria. Local ancestry inference evaluated associations with variant distribution.
Results: Overall, 6.5% of individuals carried at least one pathogenic/likely pathogenic variant considered causal (no significant difference between HF cohort with reduced ejection fraction and HF with mildly reduced ejection fraction, P = 0.500), 77.7% had at least 1 variant of uncertain significance, and 15.8% had only benign/likely benign variants observed. TTN variants accounted for nearly half of the causal findings, including 13 novel variants, with additional causal variants in MYBPC3, FLNC, BAG3, and DSP. Idiopathic dilated cardiomyopathy showed the highest yield (9.9%), but pathogenic variants were also detected in ischemic (4.6%), Chagasic HF (4.9%), and hypertensive (3.8%). Local ancestry analyses showed that variant of uncertain significance were significantly more frequent in regions with African and Native American ancestry.
Conclusions: These findings replicate a significant diagnostic yield of molecular genetic testing in individuals with dilated cardiomyopathy but extend the relevance of genetic testing beyond traditionally selected HF subgroups. They also underscore the importance of including non-European and admixed populations in cardiovascular genomics to reduce interpretation bias and improve equity in precision medicine.
Related
- Natural genetic diversity modulates structural stability changes caused by pathogenic variants in small proteins
- Whole-genome sequencing of 197 cases with Parkinson’s disease reveals novel pathogenic variants in the Indian population
- Male breast cancer: clinicopathological features and prevalence of germline pathogenic variants
- The population frequency of predicted pathogenic variants in the genes associated with Autosomal Dominant Polycystic Liver Disease (ADPLD) and kidney cysts
- Association of EGLN1 and EGLN3 genetic variants with COVID-19 severity in a Mexican population
BibTeX
@article{lima2026prevalence,
title = {{Prevalence of Pathogenic Genetic Variants Across Heart Failure Etiologies in an Admixed Population}},
author = {Isabella Ramos Lima and Lucas Vieira Lacerda Pires and Marcos Araújo Castro e Silva and Alfredo J. Mansur and Lygia V. Pereira and Tábita Hünemeier and José Eduardo Krieger and Alexandre C. Pereira},
journal = {JACC: Advances},
year = {2026},
month = aug,
doi = {10.1016/j.jacadv.2026.103123},
url = {https://doi.org/10.1016/j.jacadv.2026.103123},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Prevalence of Pathogenic Genetic Variants Across Heart Failure Etiologies in an Admixed Population
AU - Isabella Ramos Lima
AU - Lucas Vieira Lacerda Pires
AU - Marcos Araújo Castro e Silva
AU - Alfredo J. Mansur
AU - Lygia V. Pereira
AU - Tábita Hünemeier
AU - José Eduardo Krieger
AU - Alexandre C. Pereira
PY - 2026
DA - 2026/08/26
JO - JACC: Advances
DO - 10.1016/j.jacadv.2026.103123
UR - https://doi.org/10.1016/j.jacadv.2026.103123
AB - Background: Heart failure (HF) has multiple etiologies, but genetic testing remains mainly recommended for selected subgroups with suspected inherited cardiomyopathy. Objectives: This study identified and classified genetic variants in patients within a HF cohort with reduced ejection fraction or mildly reduced ejection fraction from diverse etiologies in an admixed population. Methods: The authors analyzed whole-genome sequencing data from 1,013 unrelated individuals in the GENIUS-HF (Genetic and ElectroNic medIcal records to predict oUtcomeS in Heart Failure patients) cohort. Rare variants in 123 ClinGen-curated cardiovascular genes were classified according to American College of Medical Genetics and Genomics (ACMG) criteria. Local ancestry inference evaluated associations with variant distribution. Results: Overall, 6.5% of individuals carried at least one pathogenic/likely pathogenic variant considered causal (no significant difference between HF cohort with reduced ejection fraction and HF with mildly reduced ejection fraction, P = 0.500), 77.7% had at least 1 variant of uncertain significance, and 15.8% had only benign/likely benign variants observed. TTN variants accounted for nearly half of the causal findings, including 13 novel variants, with additional causal variants in MYBPC3, FLNC, BAG3, and DSP. Idiopathic dilated cardiomyopathy showed the highest yield (9.9%), but pathogenic variants were also detected in ischemic (4.6%), Chagasic HF (4.9%), and hypertensive (3.8%). Local ancestry analyses showed that variant of uncertain significance were significantly more frequent in regions with African and Native American ancestry. Conclusions: These findings replicate a significant diagnostic yield of molecular genetic testing in individuals with dilated cardiomyopathy but extend the relevance of genetic testing beyond traditionally selected HF subgroups. They also underscore the importance of including non-European and admixed populations in cardiovascular genomics to reduce interpretation bias and improve equity in precision medicine.
SN - 2772-963X
ER -